Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model

Siao Yi Wang, Suresh Veeramani, Emilian Racila, Jeffrey Cagley, David C. Fritzinger, Carl Wilhelm Vogel, William St John, George J. Weiner

Research output: Contribution to journal › Article › peer-review

110 Scopus citations

Fingerprint

Dive into the research topics of 'Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds